Clinical Trial

A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 22, 2023 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.
Trial Details
NCT Number NCT05911464
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 248 participants
Start Date 2023-03-02
Primary Completion 2025-10-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2023-06-22